US stock · Healthcare sector · Medical Instruments & Supplies
Company Logo

Becton, Dickinson and Company

BDXNYSE

222.83

USD
-3.29
(-1.45%)
Market Closed
34.55P/E
18Forward P/E
1.72P/E to S&P500
63.550BMarket CAP
1.52%Div Yield
Upcoming Earnings
2 Nov-7 Nov
Shares Short
Short % of Float
- -
Short % of Shares Outs.
- -
% Held by Insiders
- -
% Held by Institutions
- -
Beta
0.59
PEG Ratio
- -
52w. high/low
277.29/222.61
Avg. Daily Volume
0.93M
Return %
Stock
S&P 500
1 year
(6.39)
(16.20)
3 years
(4.75)
22.35
5 years
26.39
44.82
Scale: |
High
Low
65.46
52.30
71.30
44.91
63.31
47.14
69.08
53.16
73.24
57.08
67.10
59.41
95.78
66.58
124.82
90.84
140.88
114.78
164.55
115.84
211.27
146.87
247.75
193.74
260.74
197.00
271.52
187.81
256.49
227.20
277.29
224.61
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
23.58
25.94
29.29
29.78
31.46
35.40
37.52
41.27
43.69
50.77
58.69
55.23
61.86
64.05
61.36
69.99
69.41
Earnings per share
3.04
3.63
4.61
5.12
5.62
5.75
5.69
6.63
6.13
3.43
4.59
5.02
1.20
4.57
3.13
7.23
6.11
FCF per share
2.40
2.70
4.24
4.23
4.74
5.02
5.87
4.71
5.64
5.41
8.66
8.33
7.63
8.78
9.78
11.81
4.65
Dividends per share
0.86
0.98
1.14
1.32
1.48
1.63
1.79
1.98
2.18
2.39
2.64
3.09
3.59
3.65
3.68
3.62
3.76
CAPEX per share
1.95
2.36
2.67
2.91
2.70
2.74
2.69
3.01
3.38
3.13
3.38
3.32
3.46
3.55
2.90
4.26
3.94
Book Value per sh.
15.50
17.79
20.20
21.39
23.19
21.83
20.13
25.84
26.14
35.38
35.89
59.14
81.26
78.10
85.19
81.85
85.84
Comm.Shares outs.
247
245
244
240
234
221
205
195
193
203
213
219
258
270
279
289
285
Avg. annual P/E ratio
16.2
16.3
13.5
10.6
10.6
11.4
11.2
12.6
16.9
37.0
32.0
35.4
181.9
50.7
75.0
33.1
34.5
P/E to S&P500
0.9
0.9
0.6
0.1
0.5
0.7
0.8
0.7
0.9
1.8
1.4
1.5
7.3
2.1
2.0
1.1
1.7
Avg. annual div. yield
1.7%
1.6%
1.8%
2.4%
2.5%
2.5%
2.8%
2.4%
2.1%
1.9%
1.8%
1.7%
1.6%
1.6%
1.6%
1.5%
1.5%
Revenue (m)
5,835
6,360
7,156
7,161
7,372
7,829
7,708
8,054
8,446
10,282
12,483
12,093
15,983
17,290
17,117
20,248
19,782
Operating margin
18.0%
18.9%
21.7%
23.0%
22.7%
22.5%
20.2%
15.6%
19.0%
10.4%
11.5%
12.2%
9.4%
10.2%
8.7%
13.8%
12.6%
Depreciation (m)
405
441
477
470
502
504
511
546
562
891
1,114
1,088
1,978
2,253
2,154
2,273
2,240
Net profit (m)
752
890
1,127
1,232
1,318
1,271
1,170
1,293
1,185
695
976
1,100
311
1,233
874
2,092
1,786
Income tax rate
27.0%
28.9%
27.4%
26.0%
29.2%
26.3%
24.6%
20.3%
22.1%
6.0%
9.0%
(12.7)%
73.5%
(4.8)%
11.3%
6.7%
6.9%
Net profit margin
12.9%
14.0%
15.7%
17.2%
17.9%
16.2%
15.2%
16.1%
14.0%
6.8%
7.8%
9.1%
1.9%
7.1%
5.1%
10.3%
9.0%
Working capital (m)
1,609
1,652
2,198
2,870
2,834
2,845
3,344
3,743
3,896
1,659
1,967
15,291
195
1,009
3,133
2,212
2,467
Long-term debt (m)
957
956
953
1,488
1,495
2,485
3,761
3,763
3,768
11,370
10,550
18,667
18,894
18,081
17,224
17,110
15,692
Equity (m)
3,836
4,362
4,936
5,143
5,435
4,828
4,136
5,042
5,053
7,165
7,634
12,948
20,994
21,082
23,765
23,677
25,493
ROIC
14.4%
15.0%
17.4%
16.7%
16.5%
15.5%
13.4%
13.3%
12.6%
4.7%
6.3%
4.9%
1.1%
4.1%
2.8%
5.4%
4.7%
Return on capital
15.1%
16.9%
19.6%
18.3%
19.2%
17.3%
14.7%
13.7%
13.3%
4.1%
5.7%
4.0%
3.5%
3.5%
2.8%
5.0%
4.4%
Return on equity
19.6%
20.4%
22.8%
23.9%
24.2%
26.3%
28.3%
25.6%
23.5%
9.7%
12.8%
8.5%
1.5%
5.8%
3.7%
8.8%
7.0%
Plowback ratio
71.8%
73.1%
75.3%
74.3%
73.8%
71.6%
68.6%
70.1%
64.5%
30.2%
42.4%
38.5%
(198.1)%
20.2%
(17.4)%
49.9%
40.0%
Div.&Repurch./FCF
86.4%
84.5%
62.1%
82.1%
94.0%
160.0%
30.5%
42.0%
38.6%
44.3%
30.5%
37.1%
47.1%
21.0%
(69.3)%
81.9%
137.3%
Capital Structure
4 Aug · 2022 | Q3
All numbers in millions
Total liabilities
$ 27,706
Total assets
$ 53,199
Long-term debt
$ 15,692
Cash and equiv.
$ 2,558
Goodwill
$ 23,968
Retained earnings
$ 15,088
Common stock
285
Enterprise Value
$ 76,684
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
566
2,845
2,295
Receivables
2,345
2,398
2,497
Inventory
2,579
2,743
2,866
Other
1,174
3,272
2,927
Current assets
6,664
8,969
8,838
Acc. Payable
1,092
1,355
1,793
Debt due
1,309
706
500
Other
3,254
3,775
4,333
Current liabilities
5,655
5,836
6,626
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
18.29%
14.41%
11.89%
Cash flow
25.17%
17.17%
14.56%
Earnings
139.36%
83.74%
38.77%
Dividends
2.14%
12.37%
12.79%
Book value
(0.37)%
18.73%
23.89%
Insider Trading
Type
Shares
Date
Delorefice Christopher
InKind
506
09/07/22
Delorefice Christopher
Award
2,674
09/01/22
Polen Thomas E Jr
Exempt
15,000
08/15/22
Polen Thomas E Jr
Sale
9,500
08/15/22
Polen Thomas E Jr
Return
5,500
08/15/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
4,225
4,253
3,855
4,784
17,117
2021
5,315
4,907
4,890
5,135
20,247
2022
4,995
5,011
4,641
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.00
0.66
1.03
0.46
3.14
2021
3.47
1.03
1.81
0.92
7.23
2022
2.38
1.59
1.37
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.90
0.91
0.96
0.91
3.68
2021
0.91
0.91
0.90
0.90
3.62
2022
0.95
0.95
0.95
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
CEO:
Mr. Thomas Polen
Full-time employees:
75,000
City:
Franklin Lakes
Address:
1 Becton Dr
IPO:
Sep 25, 1963
Website:
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.